Heart Failure Clinical Trial

ANTHEM-HFrEF Pivotal Study

Summary

A multi-center randomized controlled clinical trial to evaluate Autonomic Regulation Therapy with the VITARIA system in patients with symptomatic heart failure and reduced ejection fraction.

View Full Description

Full Description

ANTHEM-HFrEF is a multi-center, open-label, randomized controlled clinical trial with an adaptive design. Patients with symptomatic heart failure and reduced LVEF will be enrolled and randomized 2:1 to receive VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy (therapy), or to continue receiving stable guideline-directed medical therapy alone (control arm).

Subjects in the therapy arm will receive continuous, periodic VNS stimulation after surgery is completed, and will undergo visits for VNS up titration over a period of 3 months. Subjects in the control arm will also undergo scheduled visits at a similar frequency as the titration visits that are scheduled for subjects in the therapy arm. Data for safety and efficacy assessments will be collected for both study arms at 4 weeks post-randomization, every 3 months for the first 12 months, and every 4 months thereafter.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age 18 or above
Willing and capable of providing informed consent
Capable of participating in all testing associated with this clinical investigation
Stable, guideline-directed medical therapy for at least 4 weeks before subject screening. Unrestricted changes in diuretics are allowed during the 4 weeks, as long as the subject remains on a diuretic. If the use of an ARNI is being contemplated for a study subject, ARNI should be administered, and GDMT optimized, before the subject is randomized. No more than a 100% increase or 50% decrease of the dosage of any medication other than a diuretic is permitted. For these medications, medication changes within a class are allowed, as long as the equivalent dosage is within these specified limits
Stable symptomatic heart failure NYHA class III; or NYHA class II with a heart failure hospitalization in the previous 12 months. HF hospitalization may include an overnight hospital or hospital-based observation unit stay with a primary diagnosis of HF, or an emergency department visit with a primary diagnosis of HF, and will in either case include documentation of intravenous HF therapy administration or other intervention for HF
Left ventricular ejection fraction (EF) ≤ 35% and left ventricular end-diastolic diameter (LVEDD) < 8.0 cm, as confirmed by the core echocardiography laboratory during screening
N-terminal pro-BNP (NT-proBNP) level of at least 800 pg/mL, as determined by the core laboratory; or NT-proBNP level of at least 1200 pg/mL, as determined by the core laboratory, for patients with permanent atrial fibrillation or reporting signs or symptoms of atrial fibrillation at the time that the NT-proBNP sample is drawn
Received a standard cardiac assessment, including history, physical exam, and electrocardiogram, and determined by a heart failure cardiologist and study surgeon to be an appropriate candidate for the study's surgical procedure
Physically capable and willing to perform repeated 6-minute walk tests associated with the study, and having a baseline distance of between 150 and 450 meters. Symptoms limiting the duration of the 6 minute walk test must be due primarily to heart failure

Exclusion Criteria:

Refractory symptomatic hypotension (systolic blood pressure below 80 mmHg)
Complete AV block treated with unipolar pacemaker therapy
Currently implanted vagus nerve stimulation (VNS) device, baroreceptor activation therapy (BAT) device, other nerve stimulator, artificial or donor heart, or ventricular assist device (VAD)
Heart failure of non-ischemic origin for less than 6 months, or due to congenital heart disease, hypertrophic obstructive cardiomyopathy, or infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis)
Moderate (3+) or severe (4+) aortic valve or mitral valve stenosis; moderate (3+) or severe (4+) aortic valve insufficiency; or severe (4+) mitral valve insufficiency
Symptomatic uncontrolled bradycardia
On renal dialysis
Involvement in any concurrent clinical study with an investigational therapy

Study is for people with:

Heart Failure

Estimated Enrollment:

533

Study ID:

NCT03425422

Recruitment Status:

Active, not recruiting

Sponsor:

LivaNova

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 22 Locations for this study

See Locations Near You

University of Alabama
Birmingham Alabama, 35294, United States
University of Arizona
Tucson Arizona, 85724, United States
Central Arkansas Veterans Healthcare System
Little Rock Arkansas, 72205, United States
Long Beach Memorial Hospital
Long Beach California, 90806, United States
Greater Los Angeles VA Medical Center
Los Angeles California, 90073, United States
Hartford Hospital
Hartford Connecticut, 06102, United States
First Coast Cardiovascular Institute
Jacksonville Florida, 32256, United States
UnityPoint Health - Methodist Hospital
Peoria Illinois, 61606, United States
Indiana University Health Ball Memorial Hospital
Muncie Indiana, 47303, United States
Tufts Medical Center
Boston Massachusetts, 02111, United States
Lahey Medical Center
Burlington Massachusetts, 01805, United States
Michigan Heart, PC
Ypsilanti Michigan, 48197, United States
University of Mississippi Medical Center
Jackson Mississippi, 39216, United States
Mount Sinai School St. Luke's
New York New York, 10025, United States
MetroHealth System
Cleveland Ohio, 44109, United States
ProMedica Northwest Ohio Cardiology Consultants
Toledo Ohio, 43606, United States
Penn State Health Milton Hershey Medical Center
Hershey Pennsylvania, 17033, United States
Pinnacle Health
Wormleysburg Pennsylvania, 17043, United States
Baylor St. Luke's Medical Center
Houston Texas, 77030, United States
Tyler Cardiovascular Consultants
Tyler Texas, 75701, United States
Providence Sacred Heart Medical Center
Spokane Washington, 99204, United States
University of Wisconsin
Madison Wisconsin, 53792, United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Estimated Enrollment:

533

Study ID:

NCT03425422

Recruitment Status:

Active, not recruiting

Sponsor:


LivaNova

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider